REG - Haleon PLC Haleon Netherlands Haleon UK Capital - EMTN programme: publication of base prospectus

HALEONAnnouncement

07/05/2024 09:30

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240507:nRSG4068Na&default-theme=true

RNS Number : 4068N  Haleon PLC  07 May 2024

 

 

 

EMTN programme: publication of base prospectus

7 May 2024: Haleon plc (the "Company") (LSE/NYSE: HLN) today announces that,
following a routine annual update, the base prospectus dated 3 May 2024
regarding Haleon UK Capital plc's and Haleon Netherlands Capital B.V.'s
£10,000,000,000 Euro Medium Term Note ("EMTN") Programme, guaranteed by the
Company, has been published (the "Base Prospectus").

 

A copy of the Base Prospectus is available for inspection at and can be
downloaded from:

https://www.haleon.com/investors/debt-investors
(https://www.haleon.com/investors/debt-investors) .

 

Enquiries:

 Investors                                    Media

 Sonya Ghobrial          +44 7392 784784      Zoe Bird            +44 7736 746167
 Rakesh Patel            +44 7552 484646      Gemma Thomas        +44 7985175048
 Emma White              +44 7823 523562

 Email: investor-relations@haleon.com         Email: corporate.media@haleon.com

 

 

About Haleon

Haleon (LSE / NYSE: HLN) is a global leader in consumer health, with a purpose
to deliver better everyday health with humanity. Haleon's product portfolio
spans five major categories - Oral Health, Pain Relief, Respiratory Health,
Digestive Health and Other, and Vitamins, Minerals and Supplements (VMS). Its
long-standing brands - such as Advil, Sensodyne, Panadol, Voltaren, Theraflu,
Otrivin, Polident, parodontax and Centrum - are built on trusted science,
innovation and deep human understanding.

 

For more information, please visit www.haleon.com (http://www.haleon.com)
.

 

Disclaimer

Please note that the information contained in the Base Prospectus may be
addressed to and/or targeted at persons who are residents of particular
countries (specified in the Base Prospectus) only and is not intended for use
and should not be relied upon by any person outside these countries and/or to
whom the offer contained in the Base Prospectus is not addressed.  Prior to
relying on the information contained in the Base Prospectus, you must
ascertain from the Base Prospectus whether or not you are part of the intended
addressees of the information contained in the Base Prospectus.

 

Your right to access this service is conditional upon complying with the above
requirement.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  PDIGIGDUXDGDGSR